Article

Mesotheliomas with small cell features: report of eight cases.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Modern Pathology (Impact Factor: 6.36). 01/2012; 25(5):689-98. DOI: 10.1038/modpathol.2011.202
Source: PubMed

ABSTRACT Mesotheliomas with small cell morphology are rare and only one study of such cases has been published. As a result of their rare occurrence, some investigators have cast doubt on the existence of such a histologic variant of mesothelioma. This investigator reports a series of eight cases of epithelioid mesothelioma with small cell features, all of which originated in the pleura. Seven of the patients were men and one was a woman. Four patients had a history of asbestos exposure. Histologically, four of the mesotheliomas were epithelioid and four biphasic. The proportion of small cells seen in these cases constituted 80 to 100% of the tumor included in the biopsy material and 15 to 20% of the tumor present in the pneumonectomy specimens. Immunoreactivity for calretinin, keratin 5/6, keratin 7, pan-keratin, WT1, podoplanin, and mesothelin was seen in all cases tested for these markers. All of the cases were negative for MOC-31, Ber-EP4, CEA, CD15, TAG-72, TTF-1, chromogranin A, synaptophysin, CD99, and desmin. The mean survival of the six patients for whom this information was available was 8.2 months. It is important for pathologists to be aware that mesotheliomas can present small cell features and, because of this, they can be confused with other malignancies that can exhibit similar morphology. The value of immunohistochemistry in the differential diagnosis of these tumors is discussed.

0 Followers
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Der Anstieg des Asbestverbrauchs in Deutschland in der Mitte der 1970er Jahre führt dazu, dass Arbeitsmediziner, Pneumologen, Thoraxchirurgen und Pathologen bis 2020 mit einer steigenden Inzidenz und Mortalität von Patienten mit Pleuramesotheliomen zu rechnen haben. Voraussetzung für die kurative operative Therapie ist die pathologisch-anatomische Tumorsicherung anhand der Biopsie und eine möglichst korrekte Stadieneinteilung. Um zu reproduzierbaren Ergebnissen in der Beurteilung maligner Pleuraerkrankungen zu kommen, sollte die pathologisch-anatomische Diagnostik maligner Pleuramesotheliome entsprechend den Richtlinien der „International Mesothelioma Interest Group“ (IMIG) erfolgen. Gegenwärtig verwandte multimodale thoraxchirurgische Therapiekonzepte stellen die pathologisch-anatomische Diagnostik vor neue Aufgaben und Probleme, die im Folgenden vorgestellt werden.
    Der Chirurg 06/2013; 84(6). DOI:10.1007/s00104-012-2431-6 · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Deciduoid mesothelioma is a rare variant of epithelioid mesothelioma that was initially considered to occur exclusively in the peritoneum of young women who had no history of asbestos exposure and to be characterized by an aggressive clinical course, but it was later demonstrated that this tumor could also occur in the pleura of older men and women who had been exposed to asbestos. Some subsequent studies have also indicated that the clinical course is no different from that of conventional epithelioid mesothelioma. Herein are reported 21 cases of deciduoid mesothelioma that were investigated using a large panel of immunohistochemical markers, 9 of which were also studied by electron microscopy. Fifteen of the patients were male and 6 were female (mean age, 60 years). Seventeen of the cases originated in the pleura and four in the peritoneum. Histologically, all of the cases were composed of large, polygonal or ovoid cells with well-defined cell borders, dense eosinophilic cytoplasm, and single or multiple nuclei. In some cases, the cells exhibited a wide variation in their size and shape, frequent loss of cell cohesion, marked nuclear atypia, and high mitotic activity (>5 per 10 HPF); whereas, in others, the cells were more cohesive, less pleomorphic, and the mitotic activity low. As the survival of patients in the first group of cases was shorter (mean, 7 months), when compared with that of the latter (mean, 23 months), it is concluded that the differences in prognosis reported in deciduoid mesothelioma are due to the existence of a high-grade subgroup that presents highly aggressive clinical behavior. Therefore, when a high-grade deciduoid mesothelioma is present, it should be reported as it can significantly affect prognosis and treatment. The use of immunohistochemistry and electron microscopy in assisting in the differential diagnosis of deciduoid mesothelioma is also discussed.Modern Pathology advance online publication, 8 June 2012; doi:10.1038/modpathol.2012.105.
    Modern Pathology 06/2012; DOI:10.1038/modpathol.2012.105 · 6.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A large number of immunohistochemical markers that can assist in the differential diagnosis of epithelioid mesotheliomas are currently available. Because these markers are expressed differently in the various types of carcinomas that can metastasize to the serosal membranes and can potentially be confused with epithelioid mesothelioma, their selection for inclusion in a diagnostic panel largely depends on the differential diagnosis, as well as on which ones work the best in a given laboratory. Traditionally, the panels used in the differential diagnosis of epithelioid mesothelioma have consisted of a combination of positive mesothelioma markers and broad-spectrum carcinoma markers. At present, a wide variety of organ-associated carcinoma markers such as thyroid transcription factor-1 and napsin A for the lung, PAX 8 and PAX 2 for the kidney, and Müllerian-derived tumors; gross cystic disease fluid protein-15 and mammaglobin for the breast; and CDX2 for intestinal differentiation are available, which can assist in establishing the site of origin of an adenocarcinoma when included in a diagnostic panel. This article provides updated information on the composition of the panels of markers recommended in the various differential diagnoses.
    Human pathology 09/2012; 44(1). DOI:10.1016/j.humpath.2012.05.014 · 2.81 Impact Factor